Gilead Sciences (NASDAQ:GILD)

Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Hepatitis Virus

Opposing Views on Gilead Hepatitis C Presentation

Abstracts from the upcoming European Association for the Study of the Liver (EASL) conference have been published and analysts are doing their best to make sense of them. Gilead Sciences ...
Read Full Story »
payoff

5 Stocks to Buy for Big Revenue Growth

With the stock market trading at one of the highest multiples in years, investors looking to stay long stocks need to find companies that are showing significant top line growth. ...
Read Full Story »
research

Major Biotech Is So-So for Short Sellers

The short interest data are out for the March 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
investor research

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

There are two events in the biotech world that can quickly bring down the price of a stock. One is to have a failed or, sometimes worse, a misunderstood clinical ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Chesapeake, eBay, Enterprise, Gilead, Newmont, Wynn and More

Stocks were indicated marginally lower on Thursday after a post-FOMC rally on Wednesday. The one trend that keeps holding true is that investors buy stocks after every sell-off, something that ...
Read Full Story »
Euro

How the Weaker Euro Is Impacting Biotech Earnings

It is no secret that a strong dollar and a weak euro, and foreign currency environment, are acting to hurt U.S. corporate earnings. Many investors might think that biotech earnings ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get More Aggressive on Big Biotech

The short interest data are out for the February 27 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Wall Street/NYSE

After Apple Added to DJIA, at Least 3 More Dow Stocks Could Get Booted

The team members at the S&P Dow Jones Indices group made a bold decision by removing AT&T Inc. (NYSE: T) from the Dow Jones Industrial Average (DJIA) and replacing it ...
Read Full Story »
payoff

5 US Companies Focused on Returning Capital to Shareholders

If the 2008 recession and stock market calamity taught one lesson to chief financial officers of major corporations, it was one of lowering leverage, issuing less new debt and taking ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Comfortable hospital bed

Top UBS Health Care Stocks to Buy for 2015 and Beyond

As the market surges higher, investors start to get a touch more concerned about where they allocate capital. One sector that is consistently ranked as an overweight from almost every ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Wall Street

Insider Buying Stays Solid as Market Races Toward Record Highs

The stock market continues to act like an aging prize-fighter, one that will not give up despite all the haymakers landed. With conflicting economic data, rising job layoffs from the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »